Opus Genetics is trading 59.91% up now at $6.81 after positive low-dose Cohort 1 results from its BIRD-1 Phase 1/2 trial.
- All five participants showed clinically meaningful visual-function improvement, with no serious adverse events, dose-limiting toxicities, or intraocular inflammation.
- The company reported FDA alignment on potential Phase 3 endpoints and plans to begin pivotal-trial dosing in 2027.
- The stock is making a sharp, catalyst-driven move during active morning trading.